Sign up to save your podcasts
Or
Share Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.
View all episodes
By BiotechTV
5
22 ratings
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.
More shows like BiotechTV - News
View all
Economist Podcasts
4,235 Listeners
Planet Money
30,752 Listeners
Hidden Brain
43,883 Listeners
Acquired
4,205 Listeners
Invest Like the Best with Patrick O'Shaughnessy
2,304 Listeners
The Readout Loud
323 Listeners
The Journal.
5,941 Listeners
BioCentury This Week
32 Listeners
Dwarkesh Podcast
431 Listeners
Huberman Lab
29,276 Listeners
Business Breakdowns
343 Listeners
Biotech Hangout
17 Listeners
BioVenture VoiCes with Chris Garabedian
5 Listeners
Off-Target Effects with Matt Gline
4 Listeners
The Studio at Kendall Square
0 Listeners
Biotech CEO Sisterhood
2 Listeners